HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J skin care buy

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson Consumer France SAS has entered into an agreement to acquire French skin care marketer Groupe Vendome, company reports March 23. Groupe Vendome's portfolio of adult and baby care brands include Le Petit Marseillais, a line of shower gels, soaps, baths and hair care products, Laboratories Vendome, a dermatologist-positioned collection, and Prim'Age baby toiletries. Deal is expected to close in the second quarter, according to J&J...

You may also be interested in...



Finance In Brief

J&J Q3: U.S. consumer sales were $1.14 bil. in the third quarter, representing an increase of 5.9% over the prior-year period, Johnson & Johnson announces Oct. 17. Worldwide consumer sales were $2.46 bil., an increase of 10.1% over the prior year, boosted in part by the international growth of skin care products primarily reflecting the recent acquisition of French skin care marketer Groupe Vendome (1"The Rose Sheet" March 27, 2006, In Brief). The sales performance included a 2% positive impact from currency...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel